US2021128721A1PendingUtilityA1

Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

56
Assignee: MODERNATX INCPriority: Feb 1, 2017Filed: Nov 18, 2020Published: May 6, 2021
Est. expiryFeb 1, 2037(~10.5 yrs left)· nominal 20-yr term from priority
Inventors:Eric Yi-Chun HuangSze-Wah TseJared IacovelliKristine MckinneyNicholas Valiante
Y02A50/30C07K 14/7051A61P 35/00A61K 2039/575A61K 2039/572A61K 2039/55561A61K 2039/53A61K 39/39A61K 39/001164A61K 39/0011A61K 9/5123A61K 9/5015A61K 9/0019A61K 2039/585A61K 2039/54A61K 45/06A61K 2300/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an immunomodulatory therapeutic composition comprising an mRNA formulated in a lipid nanoparticle (LNP), wherein:
 the mRNA comprises an open reading frame encoding a concatemer of four KRAS activating oncogene mutation peptides, each of the KRAS activating oncogene mutation peptides having an amino acid sequence independently selected from the group consisting of SEQ ID NOs: 121, 36, 39, 122, 37, 40, 123, 38, 41, 124, 125,and 72,   thereby treating cancer in the subject.   
     
     
         3 . The method of  claim 2 , wherein the concatemer comprises the KRAS activating oncogene mutation peptides having SEQ ID NOs: 39, 40, 41, and 72. 
     
     
         4 . The method of  claim 2 , wherein the concatemer comprises, from N- to C-terminus, the KRAS activating oncogene mutation peptides having respectively the amino acid sequences of SEQ ID NOs: 39, 40, 41, and 72. 
     
     
         5 . The method of  claim 2 , wherein the concatemer comprises amino acid sequence SEQ ID NO: 137. 
     
     
         6 . The method of  claim 2 , wherein the open reading frame comprises nucleotide sequence SEQ ID NO: 169. 
     
     
         7 . The method of  claim 6 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         8 . The method of  claim 2 , wherein the mRNA comprises nucleotide sequence SEQ ID NO: 167. 
     
     
         9 . The method of  claim 8 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         10 . The method of  claim 2 , wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid:about 5-25% phospholipid:about 25-55% sterol: and about 0.5-15% PEG-modified lipid. 
     
     
         11 . The method of  claim 2 , wherein the LNP comprises a molar ratio of about 20-60% Compound 25:about 5-25% DSPC:about 25-55% cholesterol:about 0.5-15% PEG-DMG. 
     
     
         12 . The method of  claim 2 , wherein the LNP comprises a molar ratio of about 50% Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5% PEG-DMG. 
     
     
         13 . The method of  claim 2 , wherein treating cancer comprises reducing or decreasing the size of a tumor, inhibiting tumor growth, or inducing an anti-tumor immune response in the subject. 
     
     
         14 . The method of  claim 13 , wherein the anti-tumor immune response comprises T cells specific for any one of the KRAS activating oncogene mutation peptides. 
     
     
         15 . The method of  claim 2 , wherein the cancer is metastatic colorectal cancer, non-small cell lung cancer (NSCLC), or pancreatic cancer. 
     
     
         16 . The method of  claim 2 , wherein the subject has a histologically confirmed HLA subtype selected from HLA-A11 and/or HLA-C*08. 
     
     
         17 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an immunomodulatory therapeutic composition, comprising:
 an mRNA comprising an open reading frame encoding a concatemer of 3-10 KRAS activating oncogene mutation peptides, wherein each peptide is about 10-30 amino acids in length, and wherein each peptide comprises a mutation independently selected from the group consisting of G12D, G12V, G12C, G12S, G12A, G12R and G13D mutations in human KRAS of SEQ ID NO: 166,   thereby treating cancer in the subject.   
     
     
         18 . The method of  claim 17 , wherein the mutations are independently selected from the group consisting of the G12D, G12V, G12C and G13D mutations. 
     
     
         19 . The method of  claim 17 , wherein the concatemer comprises 4 peptides. 
     
     
         20 . The method of  claim 17 , wherein each peptide is about 15-25 amino acids in length. 
     
     
         21 . The method of  claim 17 , wherein at least two of the peptides are linked directly to one another without a linker. 
     
     
         22 . The method of  claim 17 , wherein the mRNA comprises 200, 300, 400, 500, 600, 700, 800, or 900 nucleotides. 
     
     
         23 . The method of  claim 17 , wherein the concatemer is a 100-mer concatemer. 
     
     
         24 . The method of  claim 17 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         25 . The method of  claim 17 , wherein the mRNA is formulated in an LNP. 
     
     
         26 . The method of  claim 25 , wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid:about 5-25% phospholipid:about 25-55% sterol:about 0.5-15% PEG-modified lipid. 
     
     
         27 . The method of  claim 25 , wherein the LNP comprises a molar ratio of about 20-60% Compound 25:about 5-25% DSPC:about 25-55% cholesterol:about 0.5-15% PEG-DMG. 
     
     
         28 . The method of  claim 25 , wherein the LNP comprises a molar ratio of about 50% Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5% PEG-DMG. 
     
     
         29 . The method of  claim 17 , wherein treating cancer comprises reducing or decreasing the size of a tumor, inhibiting tumor growth, or inducing an anti-tumor immune response in the subject. 
     
     
         30 . The method of  claim 29 , wherein the anti-tumor immune response comprises T cells specific for any one of the KRAS activating oncogene mutation peptides. 
     
     
         31 . The method of  claim 17  wherein the cancer is metastatic colorectal cancer, non-small cell lung cancer (NSCLC), or pancreatic cancer. 
     
     
         32 . The method of  claim 17 , wherein the subject has a histologically confirmed HLA subtype selected from HLA-A11 and/or HLA-C*08. 
     
     
         33 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an immunomodulatory therapeutic composition, comprising:
 an mRNA comprising an open reading frame encoding a concatemer of four KRAS activating oncogene mutation peptides, wherein each peptide is about 10-30 amino acids in length, wherein each peptide comprises a mutation independently selected from the group consisting of G12D, G12V, G12C, and G13D mutations in human KRAS of SEQ ID NO: 166, and wherein the peptides are linked directly to one another without a linker,   thereby treating cancer in the subject.   
     
     
         34 . The method of  claim 33 , wherein the peptides are about 15-25 amino acids in length. 
     
     
         35 . The method of  claim 33 , wherein the mRNA comprises 200, 300, 400, 500, 600, 700, 800, or 900 nucleotides. 
     
     
         36 . The method of  claim 33 , wherein the concatemer is a 100-mer concatemer. 
     
     
         37 . The method of  claim 33 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         38 . The method of  claim 33 , wherein the mRNA is formulated in an LNP. 
     
     
         39 . The method of  claim 38 , wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid:about 5-25% phospholipid:about 25-55% sterol: and about 0.5-15% PEG-modified lipid. 
     
     
         40 . The method of  claim 38 , wherein the LNP comprises a molar ratio of about 20-60% Compound 25:about 5-25% DSPC:about 25-55% cholesterol:about 0.5-15% PEG-DMG. 
     
     
         41 . The method of  claim 38 , wherein the LNP comprises a molar ratio of about 50% Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5% PEG-DMG. 
     
     
         42 . The method of  claim 33 , wherein treating cancer comprises reducing or decreasing the size of a tumor, inhibiting tumor growth, or inducing an anti-tumor immune response in the subject. 
     
     
         43 . The method of  claim 42 , wherein the anti-tumor immune response comprises T cells specific for any one of the KRAS activating oncogene mutation peptides. 
     
     
         44 . The method of  claim 33 , wherein the cancer is metastatic colorectal cancer, non-small cell lung cancer (NSCLC), or pancreatic cancer. 
     
     
         45 . The method of  claim 33 , wherein the subject has a histologically confirmed HLA subtype selected from HLA-A11 and/or HLA-C*08. 
     
     
         46 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an immunomodulatory therapeutic composition comprising an mRNA formulated in an LNP, wherein:
 the mRNA comprises an open reading frame encoding a concatemer of four KRAS activating oncogene mutation peptides, the concatemer comprising amino acid sequence SEQ ID NO: 137;   the LNP comprises a molar ratio of about 20-60% Compound 25:about 5-25% DSPC:about 25-55% cholesterol:about 0.1-15% PEG-DMG; and   wherein one or more uridine nucleosides in the mRNA are N1-methylpseudouridine, thereby treating cancer in the subject.   
     
     
         47 . The method of  claim 46 , wherein the open reading frame comprises nucleotide sequence SEQ ID NO: 169. 
     
     
         48 . The method of  claim 46 , wherein the mRNA comprises nucleotide sequence SEQ ID NO: 167. 
     
     
         49 . The method of  claim 46 , wherein the LNP comprises the molar ratio of about 50% Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5% PEG-DMG. 
     
     
         50 . The method of  claim 49 , wherein the open reading frame comprises nucleotide sequence SEQ ID NO: 169. 
     
     
         51 . The method of  claim 49 , wherein the mRNA comprises nucleotide sequence SEQ ID NO: 167. 
     
     
         52 . The method of  claim 49 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         53 . The method of  claim 46 , wherein treating cancer comprises reducing or decreasing the size of a tumor, inhibiting tumor growth, or inducing an anti-tumor immune response in the subject. 
     
     
         54 . The method of  claim 53 , wherein the anti-tumor immune response comprises T cells specific for any one of the KRAS activating oncogene mutation peptides. 
     
     
         55 . The method of  claim 46 , wherein the cancer is metastatic colorectal cancer, non-small cell lung cancer (NSCLC), or pancreatic cancer. 
     
     
         56 . The method of  claim 46 , wherein the subject has a histologically confirmed HLA subtype selected from HLA-A11 and/or HLA-C*08. 
     
     
         57 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an immunomodulatory therapeutic composition comprising an mRNA formulated in an LNP, wherein:
 the mRNA comprises an open reading frame encoding a concatemer of four KRAS activating oncogene mutation peptides, each of the KRAS activating oncogene mutation peptides having an amino acid sequence independently selected from the group consisting of SEQ ID NOs: 39, 40, 41, and 72,   thereby treating cancer in the subject.   
     
     
         58 . The method of  claim 57 , wherein all uridine nucleosides in the mRNA are N1-methylpseudouridine. 
     
     
         59 . The method of  claim 57 , wherein the LNP comprises a molar ratio of about 20-60% ionizable amino lipid:about 5-25% phospholipid:about 25-55% sterol:about 0.5-15% PEG-modified lipid. 
     
     
         60 . The method of  claim 57 , wherein the LNP comprises a molar ratio of about 20-60% Compound 25:about 5-25% DSPC:about 25-55% cholesterol:about 0.5-15% PEG-DMG. 
     
     
         61 . The method of  claim 57 , wherein the LNP comprises a molar ratio of about 50% Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5% PEG-DMG. 
     
     
         62 . The method of  claim 57 , wherein treating cancer comprises reducing or decreasing the size of a tumor, inhibiting tumor growth, or inducing an anti-tumor immune response in the subject. 
     
     
         63 . The method of  claim 62 , wherein the anti-tumor immune response comprises T cells specific for any one of the KRAS activating oncogene mutation peptides. 
     
     
         64 . The method of  claim 57 , wherein the cancer is metastatic colorectal cancer, non-small cell lung cancer (NSCLC), or pancreatic cancer. 
     
     
         65 . The method of  claim 57 , wherein the subject has a histologically confirmed HLA subtype selected from HLA-A11 and/or HLA-C*08.

Join the waitlist — get patent alerts

Track US2021128721A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.